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ABSTRACT
Introduction Personalised cancer screening aims to 
improve benefits, reduce harms and being more cost- 
effective than age- based screening. The objective of 
the DECIDO study is to assess the acceptability and 
feasibility of offering risk- based personalised breast 
cancer screening and its integration in regular clinical 
practice in a National Health System setting.
Methods and analysis The study is designed as a 
single- arm proof- of- concept trial. The study sample 
will include 385 women aged 40–50 years resident 
in a primary care health area in Spain. The study 
intervention consists of (1) a baseline visit; (2) breast 
cancer risk estimation; (3) a second visit for risk 
communication and screening recommendations based 
on breast cancer risk and (4) a follow- up to obtain the 
study outcomes.
A polygenic risk score (PRS) will be constructed as 
a composite likelihood ratio of 83 single nucleotide 
polymorphisms. The Breast Cancer Surveillance 
Consortium risk model, including age, race/ethnicity, 
family history of breast cancer, benign breast 
disease and breast density will be used to estimate 
a preliminary 5- year absolute risk of breast cancer. A 
Bayesian approach will be used to update this risk with 
the PRS value.
The primary outcome measures will be attitude 
towards, intention to participate in and satisfaction 
with personalised breast cancer screening. Secondary 
outcomes will include the proportions of women who 
accept to participate and who complete the different 
phases of the study. The exact binomial and the 
Student’s t- test will be used to obtain 95% CIs.
Ethics and dissemination The study protocol was 
approved by the Drug Research Ethics Committee of the 
University Hospital Arnau de Vilanova. The trial will be 
conducted in compliance with this study protocol, the 
Declaration of Helsinki and Good Clinical Practice.
The results will be published in peer- reviewed scientific 
journals and disseminated in scientific conferences and 
media.
Trial registration number NCT03791008.
INTRODUCTION
The Horizon 2020 Advisory Group defines 
personalised medicine as ‘a medical model 
using characterisation of individuals’ pheno-
types and genotypes for tailoring the right 
therapeutic or preventive strategy for the 
right person at the right time’.1 Person-
alised cancer screening pursues improving 
age- based screening by detecting malignant 
tumours in younger subjects at higher risk, 
reducing harms through reduction of false- 
positive results and overdiagnosis in subjects 
at lower risk and being more cost- effective.2 3
Personalised screening for breast cancer 
consists of estimating the individual risk of 
developing breast cancer in a specific time 
horizon and providing tailored recommen-
dations for early detection that combine 
(1) frequency of the screening exams (eg, 
annual, biennial, triennial); (2) age at the 
Strengths and limitations of this study
 ► This proof- of- concept study will provide evidence 
on feasibility and acceptance of personalised breast 
cancer screening, by the target population, under a 
publicly funded health system.
 ► Breast cancer risk will be estimated using known 
risk factors and a polygenic risk score.
 ► Tailored recommendations on breast cancer screen-
ing will be provided to women by primary care doc-
tors in their health centre.
 ► Women’s attitudes towards, participating intentions 
in and satisfaction with personalised breast screen-
ing will be assessed as primary outcomes.
 ► The design of a single arm has some limitations, 
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start and end of screening and (3) screening modality 
(mammogram, ultrasound, MRI).
Personalised screening requires an accurate measure 
of individual risk. Tice et al4 developed and validated the 
Breast Cancer Surveillance Consortium (BCSC) model 
including age, race or ethnicity, breast density, family 
history of breast cancer and previous biopsy. An updated 
version of the BCSC model replaced previous biopsy 
by type of benign breast disease.5 Recently, genome 
studies have identified >90 genetic variants called single- 
nucleotide polymorphisms (SNPs) that would explain 
between 15% and 20% of the inherited variance in breast 
cancer risk.6 Michailidou et al7 identified 65 new breast 
cancer risk loci and estimated that, in total, common 
susceptibility variants explain 18% of the familial rela-
tive risk. Mavaddat et al8 proposed a polygenic risk score 
(PRS) that grouped the individual effects and the inter-
actions of 77 SNPs to estimate the risk of breast cancer. 
Vachon et al9 10 observed independence between a PRS 
similar to the previous one and breast density in case- 
control studies.
In a critical review of clinical applications of polygenic 
breast cancer risk, Yanes et al11 highlight that there is 
considerable debate about the clinical utility of polygenic 
information for assessing breast cancer risk. Whereas, 
the sceptics argue that there is not enough evidence for 
their implementation in clinical practice, the supporters 
consider that PRS have the potential of (1) providing risk 
information to women with uninformative genetic testing 
results; (2) being risk modifiers for those with patho-
genic variants in high and moderate risk genes and (3) 
providing personalised risk assessments and risk manage-
ment strategies in population screening programmes. 
In fact, the Yanes et al review11 showed that, in Euro-
pean populations, the addition of a PRS to the existing 
risk models has improved their accuracy. The highest 
area under the curve, 0.72, was reported in a model that 
combined BCSC, circulating oestradiol levels and PRS, 
for oestrogen receptor- positive breast cancer.12
Few studies have assessed the implementation of risk- 
based breast cancer screening. Román et al13 performed 
the first systematic review of studies assessing personalised 
breast cancer screening strategies and evaluated the 
quality of the evidence. Thirteen studies were included, 
three randomised controlled trials in the recruitment 
phase and no reported results yet, nine mathematical 
modelling studies and one observational pilot study. In 
all models and in the observational study, personalised 
screening strategies were shown to be effective and effi-
cient. However, as the authors indicate, evidence is 
lacking on feasibility, acceptability and the legal and 
ethical aspects of personalised screening strategies.
Evans et al14 assessed the feasibility of determining breast 
cancer risk and communicating it in the context of a 
population- based mammographic screening programme 
in England. In the Predicting Risk of Cancer At Screening 
(PROCAS) study, they used the Tyrer- Cuzick model15 
for risk assessment and investigated risk perception, the 
proportion wishing to know their 10- year risk and whether 
subsequent screening attendance was affected. Women 
at high or at low risk were invited for risk feedback and 
counselling. The authors concluded that (a) the majority 
of women wished to receive risk information; (b) percep-
tion of breast cancer risk in the general population is 
poor and (c) high- risk women increased their attendance 
to the subsequent screening. In a later analysis, Evans et 
al16 added a PRS and mammographic density to the Tyrer- 
Cuzick model, with the objective of improving breast 
cancer risk stratification and enabling more targeted 
early detection/prevention strategies in population 
screening programmes. The combined risk tool improved 
the Tyrer- Cuzick model and defined a low- risk group of 
women that was approximately 30% of the total, such that 
cancers identified in this group were significantly more 
likely to have an extremely good prognosis. According to 
the authors, in a risk- stratified approach with an assess-
ment at first mammogram around age 45–50 years, the 
extra screening in the high- risk group could be offset by 
reducing or eliminating screening in the low- risk group, 
where the benefits of screening may be outweighed by 
false- positive results and the potential for overdiagnosis 
and overtreatment.16
On the basis of the PROCAS project, and considering 
the National Institute for Health and Care Excellence 
clinical guidelines for women with familial breast cancer, 
French et al17 developed an automated system (BC- Pre-
dict) for offering an assessment of breast cancer risk to 
women when they receive their National Health Service 
Breast Screening Programme (NHSBSP) invitation, and 
generating feedback letters to communicate this risk to 
women and health professionals. The recently published 
protocol describes that the study aims at identifying and 
resolving key uncertainties regarding the feasibility of 
integrating BC- Predict into the NHSBSP.17 In addition 
to including an explicit quantitative and qualitative anal-
ysis of the effects of implementing the BC- Predict system 
in the NHSBSP, the research will assess the feasibility of 
a definitive study to evaluate whether the intervention 
translates into measurable effects on breast cancer inci-
dence and stage, and is a cost- effective use of the National 
Health Service resources.
In Spain, most of population- based screening 
programmes target women aged 50–69 years and perform 
biennial mammograms. Extending the programme to 
older or younger women has been a matter of interest 
for health policy- makers. On the one hand, opportunistic 
screening in women younger than 50 years is widely used. 
The InforMa study found that around 80% of the partic-
ipants reported previous use of screening mammograms 
before age 50 years, outside the organised screening 
programme,18 with potential harms of screening such 
as overdiagnosis and false- positive results in low- risk 
women. On the other hand, in Catalonia, the incidence 
of ductal carcinoma in situ and invasive breast cancer in 
young women increased steadily during the 1990s and the 
first decade of the 2000s, in parallel with an increase in 
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mammography use over time in women in their late 30s 
or early 40s.19 20 Including women younger than 50 years 
in risk- based screening, so low- risk women are recom-
mended to wait and high- risk women are screened, may 
improve the balance of benefits and harms of the inter-
vention, as mathematical models have shown.3
There will be several challenges to the implementation 
of personalised screening. In women, barriers related 
to their culture, socioeconomic level, personal experi-
ence, the trust in the infallibility and innocuousness of 
screening and the social alarm that cancer generates, 
among others.21 22 In healthcare professionals, some 
barriers are common with those in women and others 
are specific, such as the inertia to adapt to new evidence 
and the social pressure to avoid clinical error or delayed 
diagnosis.23–25 Two systematic reviews showed that both 
women and healthcare professionals overestimate bene-
fits and underestimate harms of treatments, screening 
and tests.26 27 In addition, women overestimate the risk of 
breast cancer and most of them have not been informed 
of the adverse effects of screening. In clinical practice, 
personalised screening probably will require more time 
than the current ‘one- size- fits- all’ approach, at least at 
the beginning. But new ways of organising, integrating 
and analysing data will allow for better identification of 
individual features that could indicate the optimal inter-
vention, at any time, while saving time and increasing 
effectiveness and efficiency. When the ongoing clinical 
trials finish, if they show that risk- based screening is 
effective and efficient with respect to the current prac-
tice, country- specific proof- of- concept studies on imple-
menting the risk- based screening approach will be of 
great value.
Study objective
The objective of the DECIDO project is to assess the 
acceptability and feasibility of offering personalised 
breast cancer screening and its integration in the usual 
clinical practice. This proof- of- concept study will assess 
the women’s attitudes, participating intentions and satis-
faction with personalised breast screening.
METHODS AND ANALYSIS
Study design
The study is designed as a single- arm proof- of- concept 
trial. A pilot study was carried out with 20 women to test 
the suitability of the recruitment and data collection 
processes and the coordination of the involved health-
care professionals.
Participants
From January 2019 onwards, 385 women aged 40–50 
years will be enrolled in the study. Potential participants 
are the 2038 women living in the ‘Primer de Maig’ Basic 
Health Area in Lleida, Catalonia, on 31 December 2018, 
that would turn 40–50 years during the following 1.5 
years, according to the primary care information system.
All the women that will turn 50 during the study period 
will be invited to participate. If they decline to partic-
ipate in the study, they will be invited to participate in 
the population- based Early Detection Programme for Breast 
Cancer, since women resident in Spain, aged 50–69 years, 
are invited biennially for a breast screening mammogram.
From women that will turn 40–49 years during the 
study period, a random sample of 20–50 women will be 
selected, on a monthly basis, and invited to participate 
until the accrual goal of 385 women is achieved.
Women with a previous diagnosis of breast cancer or a 
breast study in process, or those fulfilling clinical criteria 
for cancer genetic counselling will be excluded. Women 
not understanding or speaking Catalan or Spanish, or 
with a physical or cognitive disability that prevents breast 
screening or the main outcomes assessment will be also 
excluded.
An invitation letter with a brief summary of the study 
objectives will be mailed to the selected women. After 
1–2 weeks, a primary care doctor of the study team will 
make a phone call, provide a brief information about 
the study, determine eligibility and ask if they are inter-
ested in participating. Women that will to participate will 
be scheduled for a visit at the primary care centre. An 
informed consent form will be obtained at the beginning 
of the first visit.
Intervention
The study intervention consists of a baseline visit, the 
breast cancer risk estimation, a visit for risk communica-
tion and screening recommendations and the adminis-
tration of a follow- up questionnaire. Figure 1 shows the 
timeline of the intervention.
First visit at the primary care centre
The study intervention consists of: (1) providing detailed 
information about the study objectives by a primary care 
doctor, member of the study team; (2) providing an infor-
mative brochure about the benefits and adverse effects 
of breast cancer screening28; (3) obtaining information 
on sociodemographic variables, breast cancer risk factors, 
previous screening experience, perceived personal risk of 
breast cancer and general screening knowledge, attitudes 
and intentions; (4) obtaining a saliva sample to deter-
mine the genomic profile and (5) scheduling a screening 
mammogram with breast density measurement. For 
women that had a mammogram during the year before 
the first visit, breast density and presence/absence of 
benign lesions will be obtained from that mammogram 
and the radiologist report.
Breast density measurement and breast findings
A senior radiologist (MR- R) expert in screening will 
evaluate the mammograms of all participating women. 
Mammographic breast density will be classified according 
to the Breast Imaging Reporting and Data System (BI- 
RADS) scoring system29: almost entirely fatty (a), scattered 
areas of fibroglandular density (b), heterogeneously dense 
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(c) and extremely dense (d). Mammographic findings 
will be coded from 0 (incomplete—additional imaging 
needed) to 6 (known biopsy- proven malignancy). Addi-
tional tests will be requested in case of abnormal results 
in coordination with the hospital breast unit.
Although automated breast density methods have some 
advantages and are common practice in research, they 
were not available to us. We used the clinical BI- RADS 
system, which is the standard of care in our healthcare 
centres. Even though the BI- RADS system has a non- 
negligible degree of inter- reader and intra- reader vari-
ability in the categorisation of breast density, Kerlikowske 
et al30 found that automated and clinical BI- RADS density 
similarly predict interval and screen- detected cancer risk, 
suggesting that either measure may be used to inform 
women of their breast density. And regarding automated 
methods, which have shown high reproducibility and 
robustness, Conant et al31 suggest that more research and 
collaborative effort is needed to develop affordable, well 
validated and broadly available automated software.
SNP determination and polygenic risk score estimation
Collection, conservation and delivery of saliva samples will 
be done following the saliva collection protocol provided 
by the University of Lleida’s Proteomics and Genomics 
Service (PGS) that details the procedures and indicates 
its storage conditions until it is delivered to the PGS. The 
shipment of samples from the primary care centre will be 
done once a week. The SNP analysis will be carried out 
from genomic DNA (gDNA) extracted using a suitable 
commercial kit. If the obtained gDNA does not meet the 
quality and quantity requirements necessary for the geno-
typing, another sample of saliva will be requested.
Genotyping of the 83 SNPs will be performed using 
the matrix- assisted laser desorption ionization time- of- 
flight (MALDI- TOF) mass spectrometry technique based 
on the primer extension procedure where a DNA poly-
merase extends a primer upstream of the SNP with a set 
of dideoxynucleotide triphosphates (ddNTPs) on a PCR 
amplicon, resulting in allele- specific products for MALDI 
detection.32
The PRS will be obtained using the 85 SNPs associ-
ated with breast cancer that were listed in studies by 
Shieh et al33 or Mavaddat et al.8 Both studies used data 
from the Breast Cancer Association Consortium as part of 
the Collaborative Oncological Gene- Environment Study.
Breast cancer risk estimation
First, the BCSC V.2.0 risk model5 and the Catalan breast 
cancer incidence and mortality by all causes of death will 
be used to estimate a preliminary 5- year absolute risk 
of breast cancer. The BCSC V.2.0 model includes age, 
race/ethnicity, first- degree relatives with breast cancer, 
history of benign breast disease and mammographic 
breast density. The incidence data from the Girona and 
Tarragona cancer registries (2011 Catalan Official census, 
IDESCAT) will be averaged and the locally weighted 
smoothing (LOESS) regression will be used to smooth 
them by age groups. The baseline risk for the model 
will be obtained using the smoothed breast cancer inci-
dence rates risk factors distribution of the BCSC dataset 
as described by Gail et al.34 The combination of the BCSC 
V.2.0 hazard ratios of the risk factors’ distributions will 
provide the preliminary 5- year absolute risks of breast 
cancer.
To obtain the 5- year absolute risk that includes the PRS, 
the Shieh et al approach33 using the allele frequencies and 
odds ratios from Caucasian populations will be used. The 
PRS will be constructed as a composite likelihood ratio 
representing the individual effects of each SNP. It will be 
assumed that all the SNPs are inherited independently, 
and that there are no interactions between them. Once 
the PRS is obtained, a Bayesian approach will be used to 
update preliminary 5- year risk obtained with the BCSC 
V.2.0 model with the PRS value.
Risk communication and screening recommendations
Within 1–2 months after the first visit and once the breast 
cancer risk is obtained, a second visit will be scheduled for 
risk communication and screening recommendations. 
The visit will be performed by the same primary care 
doctor and team member that performed the first visit. 
Women will be given a report including their status for 
family history, benign lesions, breast density, PRS and two 
pictograms with the 5- year absolute risk of breast cancer, 
one with their risk and the other with the risk of a same 
age woman of the general population. The screening 
recommendations are presented in table 1. Women with 
any anomalous or suspicious finding in mammography or 
with a very high risk of breast cancer after PRS assessment 
will be referred to the public hospital breast unit and/or 
genetic counselling.
Table 1 Breast cancer screening recommendations 
according to the absolute risk of breast cancer at 5 years
Age group 
(years)
Absolute risk of breast 
cancer at 5 years
Screening 
recommendations
40–44 <1.3% Watch and wait
1.3%–1.5% Biennial
>1.5% Annual






40–50 >6% Referral to the hospital 
breast unit and/or 
genetic counselling
Absolute risk of breast cancer at 5 years for average women in 
Catalonia (Spain) aged 45 years: 1%; 50 years: 1.3%; 60 years: 
1.5%; 65 years: 1.54%.
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It is important to remark that women aged 50 years of 
age and older are invited to breast cancer screening by 
the public system, biennially. Therefore, there is no watch 
and wait recommendation for women older than 49 years.
Women who receive recommendations to be screened 
annually or biennially and do not fulfil the age or peri-
odicity criteria of the public screening programme are 
advised to inform their primary care doctors, who even-
tually may refer them to the radiology unit for screening 
mammograms at the corresponding time points.
Outcomes questionnaire at follow-up
At the end of the risk communication visit a follow- up 
questionnaire will be given to women. They will be asked 
to fill it at home and return it within 2–4 weeks. A phone 
call will remind women to return the questionnaire or to 
provide the answers by phone. The following primary and 
secondary outcomes will be obtained from the follow- up 
questionnaire.
After the study is completed, there is no plan to 
follow- up the participants. The study sample is too small 
for estimating cancer detection rates or interval cancer 
rates with accuracy.
Sample size calculation
Most of the primary and secondary outcomes can be 
expressed as proportions that will facilitate the interpre-
tation as positive or neutral- negative outcomes. With a 
sample size of 385 women, proportions will be estimated 
with a confidence of 95% and a minimum accuracy of 
0.05. Given that the target population consists of 2038 
women, a 20% participation acceptance would provide 
the needed sample size.
Participant timeline
The study started to include participants on 11 December 
2018. On 13 March 2019 participant number 252 was 
included and the next day accrual was suspended because 
of the COVID-19 pandemic. On 21 October 2020, the 
study enrolment resumed. We estimate that three addi-
tional months of accrual are needed. The participant 
timeline is detailed in figure 1.
Outcomes
Primary outcomes
The primary outcome measures will be attitude towards, 
intention to participate in and satisfaction with person-
alised breast cancer screening by participant women.
Attitude towards personalised breast cancer screening
It will be measured with a scale with three items adapted 
from Hersch et al.35 Each item ranges from 1 to 5, with a 
total score ranging from 3 to 15. One of the items asks 
participants their opinion on varying the frequency of 
screening exams depending on breast cancer risk. The 
other two items ask if participants would be satisfied to 
be invited more/less frequently in case that they had 
a higher/lower risk of breast cancer than the average 
women. Higher scores indicate more positive attitudes. A 
‘positive attitude’ is defined as a total score ≥12.
Intention to participate in personalised breast cancer screening
It will be measured with a 5- point Likert scale from defi-
nitely will (1) to definitely will not (5), adapted from 
Hersch et al.35 The variable will be dichotomised as 
intending to participate (definitely or likely) or not.
Satisfaction with personalised screening
It will be measured in a 5- point Likert scale from not at 
all satisfied (1) to extremely satisfied (5).5 36 This variable 
will be measured after 1 year of recruitment.
Secondary outcomes
Attitudes towards screening mammography
It will be measured using five items adapted from Hersch 
et al.35 Each item ranges from 1 to 5. Total scores can 
range from 5 to 25. A positive attitude is defined as a total 
score ≥20. Higher scores indicate more positive attitudes.
Attitude towards measuring breast cancer risk
One categorical variable with four categories. It asks if 
the measure of breast cancer risk will do: more harm than 
good, more good than harm, it depends, do not know. The abso-
lute and relative frequencies of the four categories will be 
obtained.36
Emotional impact of the measure of breast cancer risk
Three categorical variables with five categories, ranging 
from strongly disagree (1) to strongly agree (5). First vari-
able: the information about the individual risk of breast cancer 
provides calmness. Second variable: receiving information 
about risks produces anxiety. Third variable: the information 
about the individual risk of breast cancer makes me worry. The 
scores of the three items will not be added as a scale, they 
will be reported separately.35
Preference with regard to the current screening
Categorical variable with three categories. It asks what 
type of screening the participants would choose, person-
alised risk- based or ‘one- size- fits- all,’ which is biennial 
between 50 and 69 years in Spain.
Knowledge of the benefits and harms of breast cancer screening
Eleven conceptual knowledge questions (yes/no) and 
four numerical knowledge questions with categories 
on the effect of screening. A total of 22 marks could 
be obtained, 11 coming from the questions on concep-
tual knowledge and 11 coming from the questions on 
numerical knowledge that measured absolute and rela-
tive values of the screening outcomes. The threshold to 
define adequate knowledge is to score at least 50% of the 
available marks, including at least one numerical mark, 
on all the three screening outcome subscales that refer to 
mortality reduction, overdiagnosis and false positives.35 37
Decisional conflict
O’Connor Decisional Conflict Scale, 10- item low literacy 
version, on a scale from 0 (no decisional conflict) to 100 
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(extreme decisional conflict).38 Scores <25 are associated 
with implementing decisions; scores exceeding 37.5 are 
associated with decision delay or feeling unsure about 
implementation.
Confidence in the decision
Three Likert scale statements rated from 1 (not at all 
confident) to 5 (very confident). A total score is obtained 
summing the scores of the three items and dividing by 
three.39
Anxiety about screening participation
Six- item short form of the Spielberger State Trait Anxiety 
Inventory (STAI) on a scale from 20 to 80, with higher 
scores indicating greater levels of anxiety.40 To calculate 
the total STAI score, each item is rated from 1 (not at all) 
to 4 (very much so), scoring of the positive items (calm, 
relaxed, content) is reversed, all six scores are summed 
and the total score is multiplied by 20/6.
Perceived significance of the benefits and the adverse effects of 
screening
Women will be asked how important it is for them to 
consider the chances of (1) avoiding breast cancer death, 
(2) being diagnosed and treated for a cancer that is not harmful 
and (3) having a false positive. The response options range 
from very important (1) to not at all important (4). The 
scores of the three items will not be added as a scale, they 
will be reported separately.35
Self-efficacy
Four items ranging from strongly disagree (1) to strongly 
agree (5). Total scores can range from 4 to 20. Higher 
scores indicate higher self- efficacy.36
Experience assessment
It will be measured using five items. Each item ranges 
from 1 to 5. Total scores can range from 5 to 25. A positive 
assessment is defined as a total score ≥20. Higher scores 
indicate more positive experience assessment.36
Confidence in personalised screening
Confidence Likert scale with one item ranging from very 
low confidence (1) to very high confidence (5).36
Understanding of the individual risk and the screening 
recommendations
Two categorical variables with five categories each, 
ranging from strongly disagree (1) to strongly agree (5). 
First variable: I understood the information I received about my 
risk of breast cancer in relation to women of my age. Second 
variable: I have understood the recommendations given to me 
about the screening of breast cancer in the coming years, based on 
my risk of breast cancer. The scores of the two items will be 
reported separately.36
Time spent on risk communication
Continuous variable, number of minutes. Recorded by 
the participant doctors.
Proportion of women who accept to participate in the study
Number of women that accept to participate divided by 
number of women contacted.
Proportion of participating women who complete the different 
phases of the study
Number of women that complete the different phases 
divided by number of participating women.
Data management
The data will be collected and analysed by the DECIDO 
research team. The data will be stored securely in 
password- protected computer files and in locked cabi-
nets at the Lleida Institute for Biomedical Research 
(IRBLleida). Access to these files will be granted only to 
the research team.
Data analysis
Primary and secondary outcomes will be described with 
means and SD or medians and quartiles. For scale vari-
ables, individual items, subscales and overall scores will 
be presented. Proportions of positive responses, such as 
positive attitude or adequate knowledge, will be obtained 
as stated in the outcomes definitions.
The 95% CIs for proportions will be obtained using the 
exact binomial distribution. For means, the 95% CIs will 
be obtained assuming that the sample mean distribution 
follows the Student’s t- test distribution with n−1 df.
As a descriptive analysis, primary and secondary 
outcomes by level of knowledge of the benefits and harms 
of screening and by the age groups and screening recom-
mendations shown in table 1, will be presented.
The R programming language41 and the RStudio envi-
ronment42 will be used for the data analysis.
Patient and public involvement
Participants were not and will not be involved in the 
research process.
ETHICS AND DISSEMINATION
The study protocol was approved by the Drug Research 
Ethics Committee of the University Hospital Arnau de 
Vilanova. The trial will be conducted in compliance with 
this study protocol, the Declaration of Helsinki and Good 
Clinical Practice.
The results will be published in peer- reviewed scientific 
journals, and locally and internationally disseminated in 
scientific conferences and media.
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